Novartis most challenged for its patents, followed by Pfizer

By Kim, Jin-Gu | translator Alice Kang

21.07.13 06:00:55

가나다라 0

33 generic companies file patient suits on 8 Novartis products including Entresto

Novartis was most targeted, followed by Takeda>Pfizer>Astellas>Bayer

United, Alvogen, Boryung, Dong-A, Chong Kun Dang also targeted for its patent

Among pharmaceutical companies, Novartis was found to have received the most amount of patent challenges since 2016. Over the past five and a half years, 33 generic companies had filed a total of 121 patent suits against Novartis' 15 patents on 8 products.

In addition to Novartis, generic companies also targeted Pfizer, Boehringer Ingeheim, Astellas, and AstraZeneca.

The same went for domestic companies. United Pharma, Alvogen Korea, Boryung Pharmaceutical, and Chong Kun Dang were also challenged on their patents by generic companies.

◆Generic companies challenge patents of 8 Novartis products

On the 13th, Dailypharm’s tally of patent challenges in

Kim, Jin-Gu(kjg@dailypharm.com)

If you want to see the full article, please JOIN US (click)